JP2001524988A - タキサン(taxane)を輸送するための方法および組成物 - Google Patents
タキサン(taxane)を輸送するための方法および組成物Info
- Publication number
- JP2001524988A JP2001524988A JP54602599A JP54602599A JP2001524988A JP 2001524988 A JP2001524988 A JP 2001524988A JP 54602599 A JP54602599 A JP 54602599A JP 54602599 A JP54602599 A JP 54602599A JP 2001524988 A JP2001524988 A JP 2001524988A
- Authority
- JP
- Japan
- Prior art keywords
- tpgs
- vitamin
- composition
- taxane
- vial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 171
- 229940123237 Taxane Drugs 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 38
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 90
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 90
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 90
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 115
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 96
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 87
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 72
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 55
- 229920001223 polyethylene glycol Polymers 0.000 claims description 29
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 17
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229920001427 mPEG Polymers 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 2
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000009613 breast lymphoma Diseases 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960002479 isosorbide Drugs 0.000 claims 1
- 201000008017 ovarian lymphoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000001475 prostate lymphoma Diseases 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003427 Vitamin E Natural products 0.000 abstract description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 2
- 229940046009 vitamin E Drugs 0.000 abstract description 2
- 235000019165 vitamin E Nutrition 0.000 abstract description 2
- 239000011709 vitamin E Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 69
- 239000007787 solid Substances 0.000 description 68
- 238000009472 formulation Methods 0.000 description 60
- 239000002775 capsule Substances 0.000 description 49
- 239000000523 sample Substances 0.000 description 44
- 238000003756 stirring Methods 0.000 description 38
- 239000002244 precipitate Substances 0.000 description 32
- 235000019441 ethanol Nutrition 0.000 description 29
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 21
- 238000000926 separation method Methods 0.000 description 18
- 238000012546 transfer Methods 0.000 description 13
- 239000000693 micelle Substances 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000919269 Homo sapiens cAMP-responsive element modulator Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- NJZSMGYGWKGBPU-UHFFFAOYSA-N Taxane 1 Natural products CC(=O)OC1C(OC(C)=O)C2(C)C(OC(=O)C)CC(O)C(=C)C2C(OC(C)=O)C2CC(OC(C)=O)=C(C)C1(O)C2(C)C NJZSMGYGWKGBPU-UHFFFAOYSA-N 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- -1 but not limited to Chemical compound 0.000 description 1
- 102100029387 cAMP-responsive element modulator Human genes 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.タキサンに応答する疾病状態を治療するのに有用な組成物において、タキ サンと、ビタミンE-TPGS、ジメチルイソソルビド(DMI)、メトキシPEG 350、ク エン酸、PEG 300、およびPEG 4600からなる群より選択される少なくとも1つの 化合物とを含む組成物。 2.タキサンとビタミンE-TPGSとを含む、請求項1記載の組成物。 3.約65%から約70%のビタミンE-TPGS、約20%から約25%のDMI、および約5%から 約10%のタキサンを含む、請求項1記載の組成物。 4.クエン酸をさらに含む、請求項3記載の組成物。 5.エタノール、ビタミンE-TPGS、およびタキサンを含む、請求項1記載の組成 物。 6.約25%から約75%のビタミンE-TPGS、約25%から約75%のエタノール、および 約0.6%から約5%のタキサンを含む、請求項5記載の組成物。 7.約0.2%のクエン酸をさらに含む、請求項6記載の組成物。 8.約10%のポリエトキシル化されたひまし油をさらに含む、請求項7記載の組 成物。 9.ポリエトキシル化されたひまし油、クエン酸、ジメチルイソソルビド、ビ タミンE-TPGS、およびタキサンを含む、請求項1記載の組成物。 10.約10%のポリエトキシル化されたひまし油、約25%から約30%のジメチルイ ソソルビド、約50%から約60%のビタミンE-TPGS、約0.2%のクエン酸、および約5% から約10%のタキサンを含む、請求項9記載の組成物。 11.タキサンが、パクリタキセル、またはその誘導体、類似体、もしくはプロ ドラッグである、請求項1記載の組成物。 12.メトキシPEG 350、ビタミンE-TPGS、およびタキサンを含む、請求項1記載 の組成物。 13.約25%のメトキシPEG 350、約65%のビタミンE-TPGS、および約10%のタキサ ンを含む、請求項12記載の組成物。 14.PEG 300、ビタミンE-TPGS、およびタキサンを含む、請求項1記載の組成物 。 15.約25%のPEG 300、約65%のビタミンE-TPGS、および約10%のタキサンを含む 、請求項14記載の組成物。 16.PEG 4600、ジメチルイソソルビド、ビタミンE-TPGS、およびタキサンを含 む、請求項1記載の組成物。 17.約5%のPEG 4600、約25%のジメチルイソソルビド、約70%のビタミンE-TPGS 、および約10%のタキサンを含む、請求項16記載の組成物。 18.下記の段階を含む、タキサンに応答する疾病状態を治療するための方法: タキサンと、ビタミンE-TPGS、ジメチルイソソルビド、ポリエトキシル化され たひまし油、エタノール、メトキシPEG 350、クエン酸、PEG 300、およびPEG 46 00からなる群より選択される少なくとも1つの化合物とを含む組成物を得る段階 ;および 該組成物を、タキサンに応答する疾病状態を有する哺乳動物に投与する段階。 19.組成物が、約65%から約70%のビタミンE-TPGS、約20%から約25%のジメチル イソソルビド、および約5%から約10%のタキサンを含む、請求項18記載の方法。 20.クエン酸をさらに含む、請求項19記載の方法。 21.組成物が、約25%から約75%のビタミンE-TPGS、約25%から約75%のエタノー ル、および約0.6%から約5%のタキサンを含み、投与段階が、静脈内投与または非 経口投与からなる、請求項18記載の方法。 22.組成物が約0.2%のクエン酸をさらに含む、請求項21記載の方法。 23.組成物が、約10%のポリエトキシル化されたひまし油、約25%から約30%の ジメチルイソソルビド、約50%から約60%のビタミンE-TPGS、および約5%から約10 %のタキサンを含み、該組成物の投与段階が経口投与からなる、請求項18記載の 方法。 24.組成物が、約25%のPEG 300、約65%のビタミンE-TPGS、および約10%のタキ サンを含む、請求項18記載の方法。 25.組成物が、約5%のPEG 4600、約25%のジメチルイソソルビド、約70%のビタ ミンE-TPGS、および約10%のタキサンを含む、請求項18記載の方法。 26.タキサンに応答する疾病状態が、卵巣癌、前立腺癌、乳癌、悪性リンパ腫 、肺癌、黒色腫、カポジ肉腫、多発性嚢胞腎疾患、アルツハイマー病、マラリア 、および慢性関節リューマチからなる群より選択される、請求項18記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7745998P | 1998-03-10 | 1998-03-10 | |
US60/077,459 | 1998-03-10 | ||
PCT/US1999/005151 WO1999045918A1 (en) | 1998-03-10 | 1999-03-10 | Methods and compositions for delivery of taxanes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001524988A true JP2001524988A (ja) | 2001-12-04 |
Family
ID=22138176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54602599A Ceased JP2001524988A (ja) | 1998-03-10 | 1999-03-10 | タキサン(taxane)を輸送するための方法および組成物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20010029264A1 (ja) |
EP (1) | EP0977562B8 (ja) |
JP (1) | JP2001524988A (ja) |
KR (1) | KR20010012363A (ja) |
CN (1) | CN1255852A (ja) |
AT (1) | ATE314844T1 (ja) |
AU (1) | AU762926B2 (ja) |
BR (1) | BR9904856A (ja) |
CA (1) | CA2288240A1 (ja) |
CY (1) | CY1105690T1 (ja) |
DE (1) | DE69929313T2 (ja) |
DK (1) | DK0977562T3 (ja) |
ES (1) | ES2257038T3 (ja) |
IL (1) | IL131217A0 (ja) |
PT (1) | PT977562E (ja) |
WO (1) | WO1999045918A1 (ja) |
ZA (1) | ZA991885B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002534382A (ja) * | 1999-01-08 | 2002-10-15 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | タキサン類の薬学的調合物 |
JP2005523295A (ja) * | 2002-03-01 | 2005-08-04 | ノバガリ、ファルマ、エスアー | 難溶性薬剤の自己乳化型薬物送達システム |
JP2005537285A (ja) * | 2002-07-30 | 2005-12-08 | ワイス | ラパマイシンヒドロキシエステルを含有する非経口製剤 |
JP2005343897A (ja) * | 2004-06-02 | 2005-12-15 | Cordis Corp | Cad治療のためのタキサンの注入可能な配合物 |
JP2006514635A (ja) * | 2002-11-29 | 2006-05-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | それぞれ塩基性又は酸性薬剤化合物、界面活性剤及び生理学的に許容され得る水溶性のそれぞれ酸又は塩基を含んでなる製薬学的組成物 |
JP2009513558A (ja) * | 2003-07-18 | 2009-04-02 | アベンティス・ファーマ・ソシエテ・アノニム | タキソイドの経口投与用半固体製剤 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
EP1479382A1 (en) * | 1999-06-18 | 2004-11-24 | IVAX Research, Inc. | Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
CA2397871A1 (en) * | 2000-01-20 | 2001-07-26 | Supratek Pharma Inc. | Novel podophyllotoxin compositions |
JP2003521545A (ja) * | 2000-02-02 | 2003-07-15 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | 改良された溶解性を有するタキサン製剤 |
US6919370B2 (en) | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
EP1365759A2 (en) * | 2001-01-18 | 2003-12-03 | PHARMACIA & UPJOHN COMPANY | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
EP1461056A4 (en) * | 2001-11-26 | 2006-01-25 | Supergen Inc | PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLATED CICRIC OIL IN PHARMACEUTICAL COMPOSITIONS |
US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
BR0215184A (pt) * | 2001-12-20 | 2006-06-06 | Bristol Myers Squibb Co | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada |
EP1340497A1 (en) * | 2002-03-01 | 2003-09-03 | Novagali Sas | Self emulsifying drug delivery systems for poorly soluble drugs |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
US20040127551A1 (en) * | 2002-12-27 | 2004-07-01 | Kai Zhang | Taxane-based compositions and methods of use |
CA2511521C (en) * | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
WO2004091506A2 (en) * | 2003-04-10 | 2004-10-28 | Ivax Research, Inc. | Taxane-based compositions and methods of use |
EP1510206A1 (en) * | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
EP1713442A1 (en) * | 2004-01-30 | 2006-10-25 | Pfizer Italia S.r.l. | Semisolid matrix pharmaceutical formulations |
WO2005074889A1 (en) * | 2004-02-03 | 2005-08-18 | Dinesh Shantilal Patel | Novel compositions of taxol derivatives and the process for the manufacture thereof |
US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
EP1793806A2 (en) * | 2004-09-30 | 2007-06-13 | Eastman Chemical Company | Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
US20110038899A1 (en) * | 2008-03-28 | 2011-02-17 | Garry Thomas Gwozdz | Pharmaceutical Solutions and Method for Solublilizing Therapeutic Agents |
US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
CN102000052B (zh) * | 2008-06-25 | 2012-12-12 | 重庆市中药研究院 | 紫杉醇及其衍生物在制药中的应用 |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
EP2480208A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes |
US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
CA2798180A1 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
EP2663292B9 (en) | 2011-01-10 | 2017-11-08 | Celgene Corporation | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
JP6921759B2 (ja) | 2015-06-04 | 2021-08-18 | クリティテック・インコーポレイテッド | 捕集装置および使用法 |
RU2018113280A (ru) | 2015-09-16 | 2019-10-16 | ДиЭфБи СОРИА, ЭлЭлСи | Доставка наночастиц лекарственного средства и способы их использования |
RU2737934C2 (ru) | 2016-04-04 | 2020-12-07 | Крититек, Инк. | Способы лечения солидных опухолей |
WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
AU2018284247B2 (en) | 2017-06-14 | 2020-04-30 | Crititech Inc. | Methods for treating lung disorders |
RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
US11497726B2 (en) | 2018-03-16 | 2022-11-15 | Dfb Soria, Ll. | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228162A (en) * | 1979-07-09 | 1980-10-14 | Research Corporation | Dimethyl isosorbide in liquid formulation of aspirin |
US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
DK0674510T3 (da) * | 1992-11-27 | 1999-05-10 | Napro Biotherapeutics Inc | Injicerbart præparat omfattende paclitaxel |
EP0724452B1 (de) * | 1993-10-22 | 2000-05-24 | Hexal Ag | Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator |
US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
-
1998
- 1998-03-10 IL IL13121798A patent/IL131217A0/xx unknown
-
1999
- 1999-03-09 ZA ZA9901885A patent/ZA991885B/xx unknown
- 1999-03-10 CN CN99800022A patent/CN1255852A/zh active Pending
- 1999-03-10 DK DK99909941T patent/DK0977562T3/da active
- 1999-03-10 DE DE69929313T patent/DE69929313T2/de not_active Expired - Fee Related
- 1999-03-10 EP EP99909941A patent/EP0977562B8/en not_active Expired - Lifetime
- 1999-03-10 AT AT99909941T patent/ATE314844T1/de not_active IP Right Cessation
- 1999-03-10 AU AU29022/99A patent/AU762926B2/en not_active Ceased
- 1999-03-10 JP JP54602599A patent/JP2001524988A/ja not_active Ceased
- 1999-03-10 ES ES99909941T patent/ES2257038T3/es not_active Expired - Lifetime
- 1999-03-10 BR BR9904856-6A patent/BR9904856A/pt not_active Application Discontinuation
- 1999-03-10 KR KR19997010315A patent/KR20010012363A/ko not_active Application Discontinuation
- 1999-03-10 WO PCT/US1999/005151 patent/WO1999045918A1/en active IP Right Grant
- 1999-03-10 CA CA002288240A patent/CA2288240A1/en not_active Abandoned
- 1999-03-10 PT PT99909941T patent/PT977562E/pt unknown
-
2001
- 2001-02-28 US US09/795,626 patent/US20010029264A1/en not_active Abandoned
-
2006
- 2006-03-29 CY CY20061100438T patent/CY1105690T1/el unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002534382A (ja) * | 1999-01-08 | 2002-10-15 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | タキサン類の薬学的調合物 |
JP2010235636A (ja) * | 1999-01-08 | 2010-10-21 | Bionumerik Pharmaceuticals Inc | タキサン類の薬学的調合物 |
JP2005523295A (ja) * | 2002-03-01 | 2005-08-04 | ノバガリ、ファルマ、エスアー | 難溶性薬剤の自己乳化型薬物送達システム |
JP2005537285A (ja) * | 2002-07-30 | 2005-12-08 | ワイス | ラパマイシンヒドロキシエステルを含有する非経口製剤 |
JP2010163466A (ja) * | 2002-07-30 | 2010-07-29 | Wyeth Llc | ラパマイシンヒドロキシエステルを含有する非経口製剤 |
JP2006514635A (ja) * | 2002-11-29 | 2006-05-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | それぞれ塩基性又は酸性薬剤化合物、界面活性剤及び生理学的に許容され得る水溶性のそれぞれ酸又は塩基を含んでなる製薬学的組成物 |
JP2009513558A (ja) * | 2003-07-18 | 2009-04-02 | アベンティス・ファーマ・ソシエテ・アノニム | タキソイドの経口投与用半固体製剤 |
JP2005343897A (ja) * | 2004-06-02 | 2005-12-15 | Cordis Corp | Cad治療のためのタキサンの注入可能な配合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1255852A (zh) | 2000-06-07 |
IL131217A0 (en) | 2001-01-28 |
AU762926B2 (en) | 2003-07-10 |
KR20010012363A (ko) | 2001-02-15 |
EP0977562B8 (en) | 2006-04-26 |
EP0977562A1 (en) | 2000-02-09 |
WO1999045918A1 (en) | 1999-09-16 |
AU2902299A (en) | 1999-09-27 |
CA2288240A1 (en) | 1999-09-16 |
MX9910340A (en) | 2000-04-01 |
ES2257038T3 (es) | 2006-07-16 |
PT977562E (pt) | 2006-05-31 |
CY1105690T1 (el) | 2010-12-22 |
DE69929313D1 (de) | 2006-03-30 |
DK0977562T3 (da) | 2006-05-01 |
US20010029264A1 (en) | 2001-10-11 |
EP0977562B1 (en) | 2006-01-04 |
ZA991885B (en) | 1999-09-10 |
DE69929313T2 (de) | 2006-08-17 |
BR9904856A (pt) | 2000-07-18 |
ATE314844T1 (de) | 2006-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001524988A (ja) | タキサン(taxane)を輸送するための方法および組成物 | |
TWI233355B (en) | Oral formulations for anti-tumor compounds | |
Chen et al. | Development and characterization of self-assembling lecithin-based mixed polymeric micelles containing quercetin in cancer treatment and an in vivo pharmacokinetic study | |
PL169372B1 (en) | Method of obtaining a pharmaceutical composition containing novel derivative of taxames group | |
EP2231189B1 (en) | Drug delivery system for administration of poorly water soluble pharmaceutically active substances | |
TW200409640A (en) | Stable oxaliplatin solution formulation and pharmaceutical composition, and method for stabilizing a formulation of oxaliplatin | |
JP2002509877A (ja) | 抗癌組成物 | |
CN108348538A (zh) | 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒 | |
AU2007246077A1 (en) | Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof | |
EP1648440B1 (en) | Semi-solid formulations for the oral administration of taxoids | |
EP3454821B1 (en) | Micelles of d-alpha-tocopheryl polyethylene glycol 1000 succinate | |
WO2002030399A2 (en) | Polymer controlled delivery of a therapeutic agent | |
ES2943492T3 (es) | Formulación de cápsulas | |
JPH10507177A (ja) | Gf120918aを含む非経口医薬組成物 | |
US20100221326A1 (en) | Pharmaceutical compositions for oral use for treating patients affected by obesity | |
CN112121028B (zh) | 一种辛伐他汀固体纳米粒制剂及其制备方法 | |
CN105560182A (zh) | 注射用卡巴他赛组合物及其制备方法 | |
CN108392483A (zh) | 一种紫杉醇联合2-甲氧基雌二醇的白蛋白纳米粒的制备方法及应用 | |
US10080720B2 (en) | Pharmaceutical composition containing docetaxel | |
MXPA99010340A (en) | Methods and compositions for delivery of taxanes | |
KR100201907B1 (ko) | 비페닐디메틸디카르복실레이트를 가용화시킨 연질캅셀제 | |
KR100618012B1 (ko) | 2-메틸-티에노-벤조디아제핀 제제 | |
EP1682119A1 (en) | Discodermolide compositions | |
CZ18181U1 (cs) | Farmaceutický prostředek s obsahem taxanového derivátu, určený pro přípravu infúzního roztoku | |
CZ17261U1 (cs) | Farmaceutický prostředek s obsahem taxanového derivátu, určený pro přípravu infuzního roztoku |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060227 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090914 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091020 |